Genentech and Lonza sign agreement

Published: 17-Dec-2003

Leading biotechnology company, Genentech, from South San Francisco, CA, and Lonza Group, Basle, Switzerland have entered into a long-term manufacturing agreement under which Lonza Biologics will manufacture commercial quantities of Rituxan(Rituximab).


Leading biotechnology company, Genentech, from South San Francisco, CA, and Lonza Group, Basle, Switzerland have entered into a long-term manufacturing agreement under which Lonza Biologics will manufacture commercial quantities of Rituxan(Rituximab).

Lonza will manufacture the product for Genentech at Lonza's production facility in Portsmouth, New Hampshire. Financial terms of the agreement have not been disclosed. 'We consider Lonza to be a leader in the area of custom manufacturing, and we are pleased to announce this manufacturing agreement with them,' said David Ebersman, Genentech's senior vice president of Product Operations.

'Genentech is focused on delivering life-improving and life-saving therapies to patients. This agreement complements our current manufacturing capabilities and allows us flexibility in our existing facilities to respond to any increased demand for our therapeutic antibody products.'

You may also like